INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
HOUSE PTR/PurchaseVerified data

Josh Gottheimer bought GILD

Joint · GILEAD SCIENCES, INC. · Gilead Sciences, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
Jan 27, 2026
Disclosed
Feb 26, 2026
Disclosure timeline30 days from execution to publication · legal deadline 45 days
Jan 27 executedFeb 26, 2026 disclosed

GILD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing0 / 15

    Disclosed 30 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GILD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$469K
    3,000 sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,223 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    24
    BE
    Burkhart ErinSVP, Controllership
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$117K
    768 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$38K
    263 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BD
    Berger DietmarChief Medical Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    533 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    8
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$195K
    1,347 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MJ
    Mercier JohannaChief Comm & Corp Aff Officer
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    2,797 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    13
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    590 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    11
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$613K
    4,230 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
    GILDGILEAD SCIENCES, INC.
    Tax withholding
    		F$41K
    285 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    5
    OP
    O'Day Daniel PatrickDirector, Chairman & CEO
    GILDGILEAD SCIENCES, INC.
    Option exercise
    		M—
    8,780 sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    1
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$49K
    335 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    1
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$3,805
    26 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Option exercise · 10b5-1 plan
    		M$1,754
    26 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    8
    BJ
    Bluestone JeffreyDirector
    GILDGILEAD SCIENCES, INC.
    Open-market sale · 10b5-1 plan
    		SELL$242K
    1,658 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20033930

    Timestamps

    Event (reported)
    Jan 27, 2026
    Published
    Feb 26, 2026
    Ingested by INSIDER
    Nov 5, 06:47 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Josh Gottheimer
    Role
    JointAs filed: “JT”
    Transaction
    PurchaseAs filed: “P”
    Asset
    Gilead Sciences, Inc. - Common Stock
    Ticker
    GILD
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    Jan 27, 2026
    Notification date (reported)
    Feb 3, 2026
    Days from execution to publication
    30

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Josh Gottheimer reported a purchase of Gilead Sciences, Inc. - Common Stock (owner: joint). Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Joint
    Josh Gottheimerbioguide:G000583
    Issuer
    GILEAD SCIENCES, INC.cik:0000882095

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.